Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack, Inc. has announced the successful completion of its first human clinical study for a continuous blood glucose monitor (CBGM), which is uniquely placed in the subclavian vein for real ...

Glucotrack (GCTK) announced the successful completion of its first in human clinical study, marking a significant milestone in continuous ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Goode, PhD, President & Chief Executive Officer of Glucotrack. “With these positive results, the promise of continuous blood glucose monitoring is one step closer to reality.” The prospective ...